NCT07023640 Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
| NCT ID | NCT07023640 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Malignant Neoplasms of Brain |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-07-10 |
| Primary Completion | 2026-06-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-07-10 with a primary completion date of 2026-06-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to perform ⁶⁸Ga-DOTA-mPNE PET/CT imaging in patients with clinically suspected or confirmed malignant tumors, in order to evaluate tracer uptake in lesions and analyze CD73 expression levels. In a subgroup of up to 10 participants, dynamic PET/CT imaging will be conducted for up to 90 minutes post-injection to assess the tracer's biodistribution and pharmacokinetic properties.Correlation analyses with relevant clinical indicators (such as pathology, immunohistochemistry, and molecular markers) will be carried out to further assess the diagnostic performance and clinical value of ⁶⁸Ga-DOTA-mPNE PET/CT in guiding tumor diagnosis and treatment. This study is expected to provide a novel molecular imaging tool for malignancies and offer clear, intuitive PET/CT-based evidence to support clinical diagnosis, differential diagnosis, and therapeutic decision-making.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥18 years, with an expected survival of ≥12 weeks. 2. No prior radiotherapy or chemotherapy; eligible for surgery or biopsy to obtain pathological diagnosis. 3. At least one measurable target lesion according to RECIST version 1.1 (Response Evaluation Criteria in Solid Tumors). 4. Written informed consent obtained and able to comply with follow-up requirements. Exclusion Criteria: 1. Severe hepatic or renal dysfunction. 2. Women who are planning to conceive, currently pregnant, breastfeeding, or intend to have children during the study period are not eligible. Fertile participants must use effective contraception during the study. 3. Unable to lie flat for 30 minutes. 4. Refusal to participate in this clinical study. 5. Claustrophobia or other psychiatric disorders. 6. Any other condition deemed unsuitable for study participation by the investigator.
Contact & Investigator
Xianzhong Zhang, PhD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT07023640 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Malignant Neoplasms of Brain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07023640 currently recruiting?
Yes, NCT07023640 is actively recruiting participants. Contact the research team at jiachenhao24@163.com for enrollment information.
Where is the NCT07023640 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07023640 clinical trial?
NCT07023640 is sponsored by Peking Union Medical College Hospital. The principal investigator is Xianzhong Zhang, PhD at Peking Union Medical College Hospital. The trial plans to enroll 50 participants.